Eutilex Competitors and Similar CompaniesClear all
Eutilex's competitors and similar companies include Zymeworks and Neovii.
 Eutilex Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology. |  Zymeworks Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. |  Neovii Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
| |
Founding Date | Founding Date 2015 | Founding Date 2003 | Founding Date 2003 |
Type | Type Public | Type Public | Type Private |
Tags | |||
Locations | Locations KR HQ | Locations Vancouver, CA HQ Seattle, US | Locations Rapperswil-Jona, CH HQ Gräfelfing, DE Lexington, US |
Employees | Employees 141 | Employees 45519% increase | Employees 1193% increase |
Financial | |||
Revenue (est.) | Revenue (est.) ₩9.5b (FY, 2024) | Revenue (est.) $106m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income (₩29.5b) (FY, 2024) | Net income ($81.1m) (FY, 2025) | Net income N/A |
Funding | |||
Total funding raised | Total funding raised $ 18.9m | Total funding raised $ 125.9m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Zymeworks
HQ
Vancouver, CA
Employees
455↑ 19% increase
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
View companyNeovii
HQ
Rapperswil-Jona, CH
Employees
119↑ 3% increase
Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
View company